InvegaTreatment for Schizophrenia, Schizoaffective Disorder
FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
TITUSVILLE, N.J., September 29, 2006 -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding a New Drug Application (NDA) for paliperidone extended-release (ER) tablets for the treatment of schizophrenia.
Recognizing the importance of new treatment options in mental illness, JJPRD is evaluating the FDA letter and will work quickly to resolve the agency's questions in order to expedite approval of paliperidone ER.
JJPRD submitted a new drug application to the U.S. Food and Drug Administration in November 2005. Upon approval by U.S. regulatory authorities, paliperidone ER, a new chemical entity, will be marketed in the United States by Janssen, L.P.
Janssen, L.P., based in Titusville, N.J., is the only large pharmaceutical company in the U.S. dedicated solely to mental health. The company currently markets prescription medications for the treatment of schizophrenia and bipolar mania. Concurrently, Janssen-Cilag, NV submitted a Marketing Authorization Application to European health authorities in May 2006 seeking approval to market the medication. The paliperidone ER submissions are based on an extensive global clinical development program that involved more than 1,600 patients in 23 countries.
Paliperidone ER uses the OROS extended-release technology developed by ALZA Corporation. This technology provides a consistent release of medication over a 24-hour period leading to smooth blood plasma levels. ALZA, Janssen and JJPRD are wholly owned subsidiaries of Johnson & Johnson. The trade name for the product has not yet been determined.
A global leader in pharmaceutical research and development, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is a subsidiary of Johnson & Johnson and is committed to bringing to market high-value, cost-effective products that treat disease and significantly improve the health and lifestyles of people worldwide.
Worldwide, it is estimated that one person in every 100 develops schizophrenia, one of the most serious types of mental illness. Symptoms of schizophrenia are marked by hallucinations, delusions, depression, blunted emotions, social withdrawal and disorganized thinking.
Source: Janssen, L.P..
- NDA Submitted for Potential New Schizophrenia Treatment November 30, 2005
Posted: September 2006
- Invega Approved as Treatment for Schizophrenia in Adolescents - April 11, 2011
- Invega Approved as the First and Only Treatment for Schizoaffective Disorder - August 6, 2009
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and Invega - February 6, 2009
- FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia - August 27, 2008
- Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan's Proprietary NanoCrystal Technology - October 29, 2007
- FDA Approves Invega for Long-Term Maintenance Treatment of Schizophrenia - April 27, 2007
- Invega Approved By FDA as New Treatment for Schizophrenia - December 21, 2006
- Janssen, L.P. Selects Invega (paliperidone) Extended Release Tablets as Brand Name for Its Investigational Atypical Antipsychotic - November 10, 2006
- New Drug Application Submitted for Paliperidone - a Potential New Treatment for Schizophrenia - November 30, 2005